JP2003524600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524600A5 JP2003524600A5 JP2000570324A JP2000570324A JP2003524600A5 JP 2003524600 A5 JP2003524600 A5 JP 2003524600A5 JP 2000570324 A JP2000570324 A JP 2000570324A JP 2000570324 A JP2000570324 A JP 2000570324A JP 2003524600 A5 JP2003524600 A5 JP 2003524600A5
- Authority
- JP
- Japan
- Prior art keywords
- pro331
- pro245
- pro335
- pro266
- pro217
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000124008 Mammalia Species 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000004969 inflammatory cell Anatomy 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000037319 Hepatitis infectious Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010927 atrophic thyroiditis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 230000003494 hepatotrophic effect Effects 0.000 claims 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10085898P | 1998-09-17 | 1998-09-17 | |
| PCT/US1998/019437 WO1999014241A2 (en) | 1997-09-17 | 1998-09-17 | Compositions and methods for the treatment of immune related diseases |
| US9819437 | 1998-09-17 | ||
| US60/100,858 | 1998-09-17 | ||
| PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003524600A JP2003524600A (ja) | 2003-08-19 |
| JP2003524600A5 true JP2003524600A5 (enExample) | 2004-12-24 |
Family
ID=22281903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000570324A Pending JP2003524600A (ja) | 1998-09-17 | 1999-09-15 | 免疫関連疾患治療のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2003524600A (enExample) |
| KR (1) | KR20010085816A (enExample) |
| AU (1) | AU6498499A (enExample) |
| CA (1) | CA2343006A1 (enExample) |
| IL (1) | IL141551A0 (enExample) |
| WO (1) | WO2000015797A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019991A1 (en) * | 1999-09-15 | 2001-03-22 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US6951924B2 (en) | 1997-03-14 | 2005-10-04 | Human Genome Sciences, Inc. | Antibodies against secreted protein HTEBYII |
| US6878806B2 (en) | 1997-03-14 | 2005-04-12 | Human Genome Sciences, Inc. | Human secreted protein HTEEB42 |
| AU2002351505B2 (en) * | 2001-10-19 | 2008-04-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| WO2005051988A2 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
| US7544659B2 (en) * | 2004-08-13 | 2009-06-09 | Genentech, Inc. | Promotion of axonal regeneration |
| WO2013033271A2 (en) * | 2011-08-29 | 2013-03-07 | Derren Barken | Method to augment immune system in response to disease or injury |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| US5874230A (en) * | 1996-07-10 | 1999-02-23 | Tularik, Inc. | Assays using TRAF2-associated protein kinase polypeptides |
| WO1998011138A1 (en) * | 1996-09-12 | 1998-03-19 | Human Genome Sciences, Inc. | Chemokine alpha-4 |
| AU5383498A (en) * | 1996-12-05 | 1998-06-29 | Human Genome Sciences, Inc. | Human chemokine beta-13 |
| JP2001524814A (ja) * | 1997-03-14 | 2001-12-04 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ２８種類のヒト分泌タンパク質 |
| AU9395998A (en) * | 1997-09-17 | 1999-04-05 | Genentech Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2001516580A (ja) * | 1997-09-17 | 2001-10-02 | ジェネンテック・インコーポレーテッド | 分泌性の、および膜貫通性のポリぺプチド、およびそれをコードする核酸 |
| ES2305608T3 (es) * | 1997-11-21 | 2008-11-01 | Genentech, Inc. | Antigenos tipo a-33 y sus utilizaciones farmacologicas. |
-
1999
- 1999-09-15 WO PCT/US1999/021547 patent/WO2000015797A2/en not_active Ceased
- 1999-09-15 AU AU64984/99A patent/AU6498499A/en not_active Abandoned
- 1999-09-15 CA CA002343006A patent/CA2343006A1/en not_active Abandoned
- 1999-09-15 JP JP2000570324A patent/JP2003524600A/ja active Pending
- 1999-09-15 KR KR1020017003430A patent/KR20010085816A/ko not_active Ceased
- 1999-09-15 IL IL14155199A patent/IL141551A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516094A5 (enExample) | ||
| JP2005535290A5 (enExample) | ||
| Kakumu et al. | Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases | |
| Gershwin et al. | Primary biliary cirrhosis and mitochondrial autoantigens—insights from molecular biology | |
| Koren et al. | Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus | |
| JP2010162017A5 (enExample) | ||
| CN104569404B (zh) | 直接竞争trfia法检测喹乙醇的方法 | |
| JP2002521391A5 (enExample) | ||
| EP1691198B1 (en) | Method of detecting hepatitis c virus | |
| Platt et al. | Highly sensitive immunoadsorption procedure for detection of low-abundance proteins | |
| JP2003524600A5 (enExample) | ||
| JP2013505938A5 (enExample) | ||
| JP2006521082A5 (enExample) | ||
| CN115028712A (zh) | 一种高亲和力抗丙型肝炎病毒的全人源单克隆抗体及其用途 | |
| Dall’Aglio et al. | Study of immune complexes in bronchoalveolar lavage fluids | |
| CN116063487B (zh) | 抗人干扰素α2的兔单克隆抗体及其应用 | |
| Saito et al. | Autoantibodies by line immunoassay in patients with primary biliary cirrhosis | |
| WO2024026384A1 (en) | Assays for detection and quantitation of human endotrophin | |
| CN112505333A (zh) | 一种旋毛虫竞争elisa抗体检测试剂盒及其检测方法 | |
| EP1724285B1 (en) | Anti-HBs monoclonal antibodies | |
| JPH0213396A (ja) | 選択的免疫学的定量のためのモノクローナル抗体 | |
| CN101426936B (zh) | 乙肝表面抗原的兔单克隆抗体及其应用方法 | |
| JP2005519590A5 (enExample) | ||
| JP4117230B2 (ja) | Ｈｃｖレセプター結合を検出するためのアッセイ | |
| JPH0213394A (ja) | 非ａ非ｂ型肝炎関連抗原、それに対する特異抗体、およびそれを用いた非ａ非ｂ型肝炎関連抗原の免疫学的検出法 |